Register for our free email digests:
Latest From Kainos Medicine Inc.
Kainos Medicine’s senior vice president sat down with Scrip to talk about the progress and ambitions for its first-in-class, potentially disease modifying Parkinson's disease drug candidate. If the drug candidate successfully goes through a Phase IIa in the US, it is set to draw robust interest from multinational pharmas which are already active in the area that lacks fundamental treatments.
South Korean pharma firm Ildong and bioventure Cellivery have tied up to jointly develop an early stage, first-in-class therapy for Parkinson's disease using Cellivery's platform technology. The two hope the partnership will fundamentally change the therapeutic approach to the neurodegenerative disease.
South Korean researchers have taken a step forward in developing a disease-modifying treatment for Parkinson's disease. Kainos Medicine has licensed in an innovative candidate for the now incurable disease, KR-33493, which is set for clinical trials in the country and is expected to be a first-in-class drug that can curb dopaminergic neuronal cell death.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- Abaxis Inc.
- Senior Management
Clinton H Severson, Chmn., Pres. & CEO
Alberto R Santa Ines, VP, Fin. & CFO
Kenneth P Aron, PhD, CTO
Ross Taylor, VP, Bus. Dev. & Investor Relations
- Contact Info
Phone: (510) 675-6500
3240 Whipple Rd.
Union City, CA 94587
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.